An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs TAK 931 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 16 Nov 2017 Planned End Date changed from 30 Mar 2020 to 22 Feb 2019.
- 16 Nov 2017 Planned primary completion date changed from 30 Mar 2020 to 22 Feb 2019.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.